You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,501,417

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,501,417

Title:	Immunological compositions as cancer biomarkers and/or therapeutics
Abstract:	The present invention concerns antibodies that react immunologically with anti-tumor antigen antibodies and compositions and methods related thereto. In particular, the antibodies that react immunologically with the anti-tumor antigen antibodies are employed in therapeutic, diagnostic, and prognostic embodiments related to cancer, including breast cancer, for example.
Inventor(s):	Pohlmann; Paula R. (Nashville, TN), Mernaugh; Ray (Nashville, TN), Arteaga; Carlos (Nashville, TN)
Assignee:	Vanderbilt University (Nashville, TN)
Application Number:	12/666,566
Patent Claims:	1. A method of determining a response of a subject to an anti-cancer treatment that comprises an anti-tumor antigen antibody, the method comprising: (a) detecting, in a sample from said subject, an antibody that reacts immunologically with said anti-tumor antigen antibody, and (b) further treating said subject with said anti-tumor antigen antibody when step (a) reveals the presence of an antibody that reacts immunologically with said anti-tumor antigen antibody. 2. The method of claim 1, wherein said antibody that reacts immunologically with said anti-tumor antigen antibody is further defined as detecting an anti-idiotypic antibody that reacts immunologically with the variable region of said anti-tumor antigen antibody, wherein the presence of said anti-idiotypic antibody indicates that the subject will respond to said further treatment. 3. The method of claim 1, wherein the antibody that reacts immunologically with an anti-tumor antigen antibody comprises a polyclonal antibody, a monoclonal antibody, a recombinant ScFv (single chain fragment variable) antibody fragment, Fv, VL or VH fragment, a Fab idiotypic antibody fragment, or an anti-idiotypic antibody fragment. 4. The method of claim 1, wherein said subject has not previously received said treatment. 5. The method of claim 1, wherein said subject has previously received said treatment. 6. The method of claim 1, wherein said tumor antigen comprises HER2, (EGFR) HER1. HER3, HER4, VEGFR, CD20, or EpCAM. 7. The method of claim 1, wherein said anti-tumor antigen antibody comprises trastuzumab, cetuximab, rituximab, bevacizumab, edrecolomab, panitumumab or alemtuzumab.

Details for Patent 8,501,417

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2027-06-26
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2027-06-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2027-06-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2027-06-26
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001	⤷ Try a Trial	2027-06-26
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014	⤷ Try a Trial	2027-06-26
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004	⤷ Try a Trial	2027-06-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.